Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A, Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review. Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Karanth S, Rajan SS, Sharma G, Yamal JM, Morgan RO. Racial-ethnic disparities in end-of-life care quality among lung cancer patients: a SEER-medicare-based study. J Thorac Oncol. 2018 Aug;13(8):1083-93. doi: 10.1016/j.jtho.2018.04.014
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Skinner CS, Schildkraut JM, Calingaert B, Hoyo C, Crankshaw SS, Fish L, Susswein L, Jasper C, Reid L. Factors associated with African Americans' enrollment in a national cancer genetics registry. Community Genet. 2008 Apr 1;11(4):224-33.
Rodríguez S, Gaunt TR, O'Dell SD, Chen XH, Gu D, Hawe E, Miller GJ, Humphries SE, Day IN. Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet. 2004 Apr;13(7):715-25.
Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11(24):3039-46.